Background
colorectal cancer, HFSR, CRC, hand-foot skin reaction
ADVERSE EVENTS, COLORECTAL CANCER
In recent years, mortality and morbidity associated with colorectal cancer (CRC) have significantly increased in Japan [MKI treatment is associated with a variety of adverse events (AEs) that can significantly impact health-related quality of life (QOL). The most frequent of these AEs is hand-foot skin reaction (HFSR), which is characterized by the appearance of painful erythematous lesions localized to the palms and soles, typically early after MKI administration, followed by blistering and keratotic lesions. Prompt management of HFSR is required as symptoms often lead to treatment interruption, dosage reduction or discontinuation.Regorafenib is associated with a high incidence of HFSR, with previous studies reporting an incidence of 47% for any grade and 17% for grade 3 HFSR in the CORRECT trial [HFSR typically develops within one to two weeks of MKI administration and may occur frequently within the first two months of treatment [Currently, high-dose topical corticosteroids, urea-based topical creams (UBCs) that inhibit keratinization, [Therefore, based on the hypothesis that aluminum chloride might be useful in preventing regorafenib-related HFSR, the present study aimed to evaluate the efficacy of topical aluminum chloride in reducing HFSR severity in mCRC patients receiving regorafenib.